These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25384805)

  • 1. Adherence to medical treatment in inflammatory bowel disease patients.
    Zelante A; De Giorgi A; Borgoni R; Trevisani L; Gallerani M
    Minerva Gastroenterol Dietol; 2014 Dec; 60(4):269-74. PubMed ID: 25384805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
    Lakatos L; Czeglédi Z; Dávid G; Kispál Z; Kiss LS; Palatka K; Kristóf T; Molnár T; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovács A; Rácz I; Lakatos PL
    Orv Hetil; 2010 Feb; 151(7):250-8. PubMed ID: 20133244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.
    Lakatos PL; Czegledi Z; David G; Kispal Z; Kiss LS; Palatka K; Kristof T; Nagy F; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovacs A; Racz I; Lakatos L
    J Crohns Colitis; 2010 Sep; 4(3):283-90. PubMed ID: 21122517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
    Elkjaer M
    Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
    Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study.
    Baars JE; Zelinkova Z; Mensink PB; Markus T; Looman CW; Kuipers EJ; Van Der Woude CJ
    Aliment Pharmacol Ther; 2009 Oct; 30(8):864-72. PubMed ID: 19706149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey.
    Nahon S; Lahmek P; Saas C; Durance C; Olympie A; Lesgourgues B; Gendre JP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1270-6. PubMed ID: 21560190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
    Kluthe C; Tsui J; Spady D; Carroll M; Wine E; Huynh HQ
    Can J Gastroenterol Hepatol; 2018; 2018():4687041. PubMed ID: 29682493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
    Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
    Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease.
    Linn AJ; van Dijk L; Smit EG; Jansen J; van Weert JC
    J Crohns Colitis; 2013 Dec; 7(11):e543-50. PubMed ID: 23660489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?
    Horváth G; Farkas K; Hollósi R; Nagy F; Szepes Z; Papp M; Palatka K; Miheller P; Lakatos L; Szamosi T; Nyári T; Wittmann T; Molnár T
    Scand J Gastroenterol; 2012 Nov; 47(11):1298-303. PubMed ID: 22935014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
    Müller KE; Lakatos PL; Arató A; Kovács JB; Várkonyi Á; Szűcs D; Szakos E; Sólyom E; Kovács M; Polgár M; Nemes É; Guthy I; Tokodi I; Tóth G; Horváth Á; Tárnok A; Csoszánszki N; Balogh M; Vass N; Bódi P; Dezsőfi A; Gárdos L; Micskey E; Papp M; Cseh Á; Szabó D; Vörös P; Veres G;
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):576-82. PubMed ID: 23820399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease.
    Weizman AV; Ahn E; Thanabalan R; Leung W; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
    Aliment Pharmacol Ther; 2012 Feb; 35(3):342-9. PubMed ID: 22176478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.
    Severs M; Mangen MJ; Fidder HH; van der Valk ME; van der Have M; van Bodegraven AA; Clemens CHM; Dijkstra G; Jansen JM; de Jong DJ; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Pierik M; Ponsioen CY; Romberg-Camps MJL; Siersema PD; Jharap B; van der Woude JC; Zuithoff NPA; Oldenburg B
    Inflamm Bowel Dis; 2017 Sep; 23(9):1568-1576. PubMed ID: 28700534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.